	Application No.	Applicant(s)
Notice of Allowability	09/674,616	STOREY ET AL.
	Examiner	Art Unit
	Maury Audet	1654
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>02/07/2005</u> .		
2. The allowed claim(s) is/are 22-31.		
3. The drawings filed on <u>01 November 2000</u> are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
	•	
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB/06 Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summary Paper No./Mail Dat 8), 7. ☑ Examiner's Amendn	e

M

Application/Control Number: 09/674,616

Art Unit: 1654

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Li Cai, Attorney for Applicant, on April 27, 2005.

IN THE CLAIMS

Please replace claim 20 in its entirety, with the following new claim 31:

31. A compound of formula:

where:

X is C=O or CR_2 ;

n is an integer of value 1 to 6;

Y is R^1R^2CR -where one of R^1 and R^2 is $-NH(B)_pZ^1$ and the other

is $-CO(B)_{\alpha}Z^2$ where

p and q are integers of value 0 to 30, and

each B is independently chosen from Q or an amino acid residue,

where Q is a cyclic peptide;

Application/Control Number: 09/674,616

Art Unit: 1654

Page 3

 Z^1 and Z^2 are metal complexing agents (L) or other protecting groups, which are biocompatible groups which inhibit or suppress *in vivo* metabolism of the peptide; J and each R are independently chosen from H, C_{1-4} alkyl, C_{1-4} alkenyl, C_{1-4} alkynyl, C_{1-4} alkoxyalkyl or C_{1-4} hydroxyalkyl;

with the proviso that:

- (i) when X is CR_2 , then Z^2 is a metal complexing agent (L);
- (ii) at least one of R¹ and R² bears at least one detectable moiety suitable for diagnostic imaging of the human body;
- (iii) R^1 and R^2 include one or more of the peptide sequence consisting of NQEQVSPYTLLKG (SEQ ID NO: 2), which is a peptide fragment of α_2 -antiplasmin.

In claims 22, 24, and 30, at line 1, the number "20" has been changed to --31--.

Claim 20-21 have been cancelled without prejudice.

Conclusion

Claims 22-31 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maury Audet whose telephone number is 571-272-0960. The examiner can normally be reached from 7:00 AM - 5:30 PM, off Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached at 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1654

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

MA, 04/29/2005

CHRISTOPHER R. TATE PRIMARY EXAMINER